Entrada Therapeutics: Soft Q3 Earnings, But Builds Momentum Toward 2026 Readouts [Seeking Alpha]
Entrada Therapeutics, Inc. (TRDA)
Company Research
Source: Seeking Alpha
TRDA is heavily investing in its Duchenne muscular dystrophy pipeline, with multiple early-stage clinical programs converging on key data readouts in 2026. Despite widening losses, TRDA maintains a strong cash position of $326.8 million, sufficient to fund operations through 3Q27 and support ongoing R&D. The stock trades at a deep valuation discount due to its large cash balance, but faces amplified risk from clustered 2026 clinical catalysts. quantic69/iStock via Getty Images Thesis Entrada Therapeutics ( TRDA ) reported a 3Q25 GAAP EPS loss of -$1.06 along with a revenue figure of $1.6 million. Since earnings on November 6th, the stock is up about 25%. In the report, there was a pretty sharp decline This article was written by Analyst's Disclosure: I/we have no stock, option or similar derivative position in any of the companies mentioned, and no plans to initiate any such positions within the next 72 hours. I wrote this article myself, and it expresses my own opinion
Show less
Read more
Impact Snapshot
Event Time:
TRDA
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
TRDA alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
TRDA alerts
High impacting Entrada Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
TRDA
News
- Entrada Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)GlobeNewswire
- Entrada Therapeutics (NASDAQ:TRDA) was given a new $13.00 price target on by analysts at Roth Capital.MarketBeat
- Entrada Therapeutics Reports Third Quarter 2025 Financial Results [Yahoo! Finance]Yahoo! Finance
- Entrada Therapeutics Reports Third Quarter 2025 Financial ResultsGlobeNewswire
- Entrada Therapeutics to Present at Upcoming Investor ConferencesGlobeNewswire
TRDA
Earnings
- 11/6/25 - Miss
TRDA
Sec Filings
- 12/4/25 - Form EFFECT
- 11/25/25 - Form SCHEDULE
- 11/24/25 - Form 4
- TRDA's page on the SEC website